Thomas Hehr - Concepedia

Author

Thomas Hehr

Also Known As

Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO), T Hehr, T. Hehr, Thomas Hehr, W. Harms, Wolfgang Harms

127

Publications

Citations

H-Index

Concepts

All Affiliations

University of Tübingen Marienhospital Stuttgart Heinrich Heine University Düsseldorf Klinik Schillerhöhe Heidelberg University

About

Thomas Hehr is an author at University of Tübingen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	25	1.2K
2	Health Sciences	13	15	1.1K
3	Engineering	1	2	338
4	Cell Biology	1	1	39
5	Gastroenterology	1	1	42

Thomas Hehr

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial Ursula Nestle, Tanja Schimek‐Jasch, Stephanie Kremp, The Lancet Oncology EngineeringOncologic ImagingMedical ImagingBiomedical ImagingMolecular Imaging	2020	169
Oral Diadochokinesis in Neurological Dysarthrias Hermann Ackermann, Ingo Hertrich, Thomas Hehr Folia Phoniatrica et Logopaedica Speech KinematicsNeurological DisorderPathological SpeechSpeech Sound DisorderMedian Syllable Duration	1995	156
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer S. Eschmann, Godehard Friedel, Frank Paulsen, European Journal of Nuclear Medicine and Molecular Imaging Positron Emission TomographyOncologic ImagingRadiation TherapyNeoadjuvant Radio-chemotherapyMedicine	2006	128
Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer S. Eschmann, Frank Paulsen, Claudia Bedeshem, Radiotherapy and Oncology Positron Emission TomographyOncologic ImagingRadiation TherapyMedical ImagingHead-and-neck Cancer	2007	119
Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? S. M. Eschmann, Godehard Friedel, Frank Paulsen, European Journal of Nuclear Medicine and Molecular Imaging Advanced Lung DiseaseMedicineBronchial NeoplasmOutcome PredictorLung Cancer	2005	92
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer S. Eschmann, Godehard Friedel, Frank Paulsen, Lung Cancer Positron Emission TomographyNeoadjuvant ChemotherapyOncologic ImagingCancer DetectionMedicine	2006	85
External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis Bernhard Berger, Ute Ganswindt, Michael Bamberg, International Journal of Radiation OncologyBiologyPhysics Villonodular SynovitisMedicinePostoperative TreatmentDermatologyExternal Beam Radiotherapy	2006	78
Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study Godehard Friedel, Wilfried Budach, Juergen Dippon, Journal of Clinical Oncology Surgical OncologySurgeryMetronomic ChemotherapyCancer ChemotherapyOncology	2010	77
Organ Preservation in Rectal Cancer: The Patients' Perspective Cihan Gani, Nina Gani, Sebastian Zschaeck, Frontiers in Oncology Palliative CareSurgical OncologyRadiation TherapyGastrointestinal OncologyColorectal Surgery	2019	69
Signet Ring Cell Carcinoma of the Stomach Is Significantly Associated with Poor Prognosis and Diffuse Gastric Cancer (Lauren’s): Single-Center Experience of 160 Cases Holger G. Hass, Ute Smith, Christina Jäger, Onkologie	2011	56

Page 1